At the end of the talk, they shared a summary slide of the top complaints, which included fatigue, pain, sleep disruption, cognitive impairment and changes in appetite. Borniger thought these were all ...

SenSam reported a significant increase in net sales for the first quarter of 2025, with a 94% growth compared to the previous year, building on its impressive 63.55% revenue growth over the last ...

Daratumumab showed a decrease in disease progression or death risk vs active monitoring in patients with high-risk smoldering multiple myeloma.